Intervention study of autoimmune bullous disease with imatinib
Not Applicable
Recruiting
- Conditions
- Autoimmune bullous disease
- Registration Number
- JPRN-UMIN000030865
- Lead Sponsor
- Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) There is a history that has allergy to Imatinib. 2) It has one of the following complications. Serious heart disease or its past liver disorder, renal disorder 3) Consent Acknowledging participation in other exams within 4 weeks before acquisition. 4) In addition, patients judged unsuitable for the trial responsible doctor or shared medical doctor to safely carry out this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of severity of autoimmune bullous disease
- Secondary Outcome Measures
Name Time Method Changes in autoantibody titer in blood Changes in antibody titer in body fluid (saliva, content of blisters)